Planning Early for European Market Entry: Navigating Regulatory & Access Differences Between the US & EU
- Highlight the importance of early strategic planning for US biotechs expanding into Europe to avoid rushed launches and regulatory setbacks
- Compare FDA prerequisites and EMA expectations to identify critical divergences that can impact timelines and trial readiness
- Discuss market access procedures and lessons learned from companies like Cabaletta on how to successfully prepare for European entry